Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.9652W HIGH $9.90
Volume
845.89 K
Value Traded
2.20 M
Short % Float
2.71%
Days to Cover
8.7
+5.04%Week
+6.88%1 Month
-1%3 Month
-1.86%6 Month
-56.7%5 Year
+18.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.45 B
EPS (TTM)
0.71
P/E Ratio
11.20
Ent. Value
19.80 B
Total Shares
687.55 M
Float Shares
258.07 M
Insiders
0.06%
Institutions
56.42%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
GRFS Catalyst Timeline
Dated clinical, regulatory and corporate events for Grifols, S.A.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Grifols, S.A.
11Total events
3Upcoming
3Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
Event history 7
▲Partnership / LicenseGAMMAKEDCorporate
Kedrion announces extension of U.S. agreement with Grifols for GAMMAKED
●Last Patient Last VisitProlastin-CTrial
Last patient last visit in SPARTA trial
emphysema due to alpha-1 antitrypsin deficiencysource ↗
●Last Patient Last VisitProlastin-CTrial
Last patient last visit in SPARTA trial
emphysema due to alpha-1 antitrypsin deficiencysource ↗
◆AcquisitionCorporate
Vector BioSource enters definitive agreement to acquire four blood collection centers from Grifols Bio Supplies
▲First Patient DosedGAMUNEX-CTrial
First patient dosed in SIGMA trial evaluating GAMUNEX-C for SID
secondary immunodeficiency (SID) in patients with blood cancerssource ↗
▲First Patient DosedXembifyTrial
First patient dosed in XPERT trial evaluating XEMBIFY for CIDP
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)source ↗
Past FDA Catalysts and PDUFA Decisions
How GRFS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
7
Drugs Scored
rNPV / MCap
Top Drug
Top 12%
Small Cap(rank 80 of 657)
Percentile Rank
Commercial products (revenue basis: latest annual revenue in its 20-F, converted from EUR to USD, to Dec 2025; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Haemoderivatives | |||
| Transfusional medicine | |||
| Bio Supplies |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha-1 MP Monoclonal antibodyNCT02796937 | Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | Phase 3 | ENROLLING BY_INVITATION | 290 | Feb 1, 2029 | ||||||
| GAMUNEX-C Monoclonal antibodyNCT07540221 | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 3 | RECRUITING | 40 | Dec 31, 2027 | ||||||
| GAMUNEX-C Small moleculeNCT07582432 | Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | Phase 3 | RECRUITING | 49 | Aug 31, 2028 | ||||||
| Alpha-1 15% Small moleculeNCT07555483 | Alpha 1 Antitrypsin Deficiency | Phase 3 | RECRUITING | 40 | Sep 30, 2027 | ||||||
| Xembify Small moleculeNCT05645107 | Hypogammaglobulinemia | Phase 3 | RECRUITING | 386 | Aug 1, 2029 | ||||||
| Albutein 5% Small moleculeCompletedNCT03451292 | Decompensated Cirrhosis and Ascites | Phase 3 | COMPLETED | 410 | May 21, 2024 | ||||||
| Fibrin Sealant Grifols Monoclonal antibodyCompletedNCT03461406 | Excessive Bleeding During Surgery | Phase 3 | COMPLETED | 186 | May 20, 2022 | ||||||
| Alpha-1 MP Monoclonal antibodyCompletedNCT01983241 | Pulmonary Emphysema in Alpha-1 PI Deficiency | Phase 3 | COMPLETED | 345 | Aug 5, 2026 | ||||||
| Prolastin-C Monoclonal antibodyCompletedNCT01213043 | Emphysema | Phase 2 | COMPLETED | 30 | Jan 1, 2012 | ||||||
| GAMUNEX-C Monoclonal antibodyMarketedNCT04561115 | Primary Immunodeficiency | Phase 3 | COMPLETED | 33 | Mar 28, 2022 | ||||||
| GAMUNEX-C Monoclonal antibodyMarketedNCT04480424 | COVID-19 | Phase 2 | COMPLETED | 100 | Oct 25, 2021 | ||||||
| Alpha-1 15% Monoclonal antibodyCompletedNCT04722887 | Alpha1-Antitrypsin Deficiency | Phase 1 | COMPLETED | 17 | Aug 1, 2025 | ||||||
| GRF312 5% Small moleculeCompletedNCT07264517 | Dry Eye Disease | Phase 2 | COMPLETED | 103 | May 20, 2026 | ||||||
| IGSC 20% Monoclonal antibodyMarketedNCT02806986 | Primary Immunodeficiency | Phase 3 | COMPLETED | 61 | May 15, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every GRFS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GRFS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 1.3 % (-61.8 %) | 24.90 M | 2.50 M | -56.57% ( -3.26 M) |
GRFS Institutional Ownership Trends
GRFS Short Interest
Shares sold short, counted twice a month.
2.71%
Short % of Float
of tradable shares sold short
7.0M
Shares Sold Short
+105.0% vs prior count
8.7 High
Days to Cover
trading days of normal volume to buy every short share back
808.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GRFS ranks across every disease it competes in
Competitive Position is a premium feature
See how GRFS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGRFS News
GRFSKedrion Biopharma Announces the Extension of a U.S. Agreement with Grifols to Support Long-Term and Continued Access to GAMMAKED®
Kedrion Biopharma has announced an extension of its agreement with Grifols to continue marketing GAMMAKED®, an intravenous immunoglobulin therapy, in the U.S. This extension aims to ensure reliable access for patients suffering from primary immunodeficiency, ITP, and CIDP. The collaboration reflects a commitment to maintaining treatment continuity and supporting patients with chronic conditions.
Read more →GRFSGrifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Grifols has announced the completion of the clinical portion of its SPARTA Phase 3 trial, which evaluates the efficacy and safety of Prolastin®-C in patients with emphysema due to alpha-1 antitrypsin deficiency. The trial involved 345 participants across 37 sites in 16 countries. Topline results are anticipated by the end of 2026, marking a significant advancement in treatment options for this underdiagnosed condition.
Read more →GRFSFOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
FOXO Technologies Inc.'s subsidiary, Vector BioSource, has entered a definitive agreement to acquire four blood collection centers from Grifols Bio Supplies. This acquisition aims to enhance Vector's biospecimen sourcing capabilities and is expected to generate over $10 million in net revenues within the first year. The deal is contingent on obtaining necessary FDA licensure and regulatory approvals, with closing anticipated in late 2026.
Read more →GRFSGrifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Grifols has commenced two Phase 3 clinical trials, SIGMA and XPERT, to expand the indications for its immunoglobulin products, GAMUNEX-C and XEMBIFY. The SIGMA trial will assess GAMUNEX-C's effectiveness in patients with secondary immunodeficiency, while XPERT will compare XEMBIFY's profile against GAMUNEX-C for treating Chronic Inflammatory Demyelinating Polyradiculoneuropathy. These trials aim to enhance treatment options for patients with immune disorders.
Read more →GRFSREPEAT - Grifols deaths and harm: Patient safety & options for accountability
A press conference will address patient safety issues related to Grifols, a major plasma-derived product manufacturer. The event will cover reported adverse events, patients' legal rights, and regulatory oversight. Concerns have been raised about Grifols' practices, including the deaths of two patients and ongoing compliance issues despite Health Canada's approval.
Read more →GRFSGrifols deaths and harm: Patient safety & options for accountability
A press conference will address patient safety concerns regarding Grifols, a major plasma product manufacturer. The event will highlight reported adverse events, legal rights of patients, and the need for regulatory accountability. Despite serious compliance issues, Grifols continues to operate in Canada under a monopoly contract. The discussion aims to enhance public confidence in blood and plasma systems.
Read more →GRFSGrifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
Grifols has launched FESILTY, a new fibrinogen concentrate, in the U.S. for treating acute bleeding episodes in patients with congenital fibrinogen deficiency. Approved by the FDA, FESILTY enhances treatment options for healthcare professionals and patients. It is designed for rapid reconstitution and effective management of bleeding, although it carries some risks, including hypersensitivity reactions and thrombotic events.
Read more →GRFSGrifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
Grifols has presented findings from its Chronos-PD program, revealing that biological changes linked to Parkinson's disease can occur up to 12 years before clinical diagnosis. This groundbreaking research, showcased at the AD/PD 2026 conference, utilizes advanced proteomics and AI to identify early biomarkers, potentially enhancing early detection and treatment strategies. The study analyzed over 2,600 plasma samples, confirming existing biomarkers and discovering new ones.
Read more →GRFSGrifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease
Grifols has launched the 'Chronos-PD' initiative, supported by a $21 million grant from The Michael J. Fox Foundation, to identify plasma biomarkers that could predict Parkinson's disease years before symptoms arise. This project utilizes advanced AI and proteomics technology to analyze over 100 million plasma samples, aiming to enhance early detection and therapeutic interventions for the disease.
Read more →GRFSGrifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution
Grifols has received FDA approval for its fibrin sealant solution, VISTASEAL™, to treat surgical bleeding in pediatric patients. This approval extends the product's availability in the U.S., where it is already used in Europe. Clinical trials demonstrated over 95% efficacy in achieving hemostasis within four minutes, highlighting its potential to improve surgical outcomes.
Read more →GRFSGrifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury
Grifols has partnered with BARDA to test ocular surface immunoglobulin (OSIG) eye drops for treating eye injuries caused by sulfur mustard exposure. Successful preclinical studies could lead to FDA licensing of this treatment, marking a significant advancement in medical responses to chemical warfare injuries. Additionally, Grifols plans to initiate a phase 2 clinical trial for OSIG in treating dry eye disease in 2025.
Read more →GRFSGrifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
Grifols has received FDA approval for an expanded label for XEMBIFY, a 20% subcutaneous immunoglobulin, allowing treatment-naïve patients to start therapy without prior intravenous treatment. The approval includes biweekly dosing, supported by phase 4 trial data showing comparable Ig levels. This move aligns with Grifols' strategy to enhance its immunoglobulin portfolio for patients with primary humoral immunodeficiencies.
Read more →GRFSGrifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
Grifols' subsidiary Biotest anticipates approximately USD 1 billion in U.S. sales from its newly FDA-approved intravenous immunoglobulin, Yimmugo, over the next seven years. Yimmugo, set to launch in Q1 2025, will be distributed by Kedrion and adds to Grifols' existing immunoglobulin portfolio. The company plans to follow up with additional protein therapies in late-stage development.
Read more →GRFSGrifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
Grifols has finalized the sale of a 20% equity stake in Shanghai RAAS to Haier Group for RMB 12.5 billion. This strategic alliance aims to improve China's healthcare system by leveraging synergies between Grifols' plasma expertise and Haier's healthcare solutions. The partnership includes a 10-year extension of their exclusive albumin distribution agreement.
Read more →GRFSGrifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
Grifols has received FDA approval for Yimmugo®, an intravenous immunoglobulin treatment for primary immunodeficiencies. This marks the first U.S. approval for a product from Biotest's portfolio, which is already successful in Europe. The innovative production process at Biotest's new facility enhances product quality and supports Grifols' growth strategy, with Yimmugo expected to significantly contribute to future sales.
Read more →GRFSGrifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Grifols celebrated the 50th anniversary of its flagship Clayton, N.C. site, which has become a leader in plasma-derived medicines. The facility produces 40% of the company's global output and has quadrupled its production capacity since Grifols acquired it in 2011. The site is noted for its sustainability efforts and innovative manufacturing technologies.
Read more →GRFSGrifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
Grifols has received CE mark approval for its Procleix ArboPlex Assay, the first automated nucleic acid test designed to screen blood donors for four significant arboviruses: chikungunya, dengue, West Nile, and Zika. This innovative test aims to improve the safety of blood transfusions by accurately detecting these viruses, which are increasingly prevalent due to climate change and global connectivity. The assay will be available in markets that accept CE certification, further solidifying Grifols' commitment to transfusion safety.
Read more →GRFSGrifols announces positive topline phase 3 fibrinogen clinical trial results
Grifols announced positive topline results from the phase 3 AdFIrst trial for BT524, a fibrinogen concentrate aimed at treating acquired fibrinogen deficiency (AFD). The trial showed BT524 is as effective as standard treatments in reducing intraoperative blood loss while maintaining a strong safety profile. Regulatory processes in Europe and the U.S. are expected to begin in Q4 2024, with significant market potential.
Read more →GRFSGrifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
Grifols has successfully completed Cohort 1 of its Phase 1/2 clinical study evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15%. This study aims to provide a subcutaneous treatment option for alpha-1 antitrypsin deficiency, potentially allowing patients to self-administer their therapy at home. The results showed no safety concerns, paving the way for Cohort 2.
Read more →GRFSAraclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
Araclon Biotech reported positive final results from its Phase 2 trial of ABvac40, an Alzheimer's vaccine. The trial met primary endpoints, confirming safety and a robust immune response. Notably, ABvac40 treatment slowed disease progression by up to 38% compared to placebo. The results suggest ABvac40's potential as a therapeutic candidate for early Alzheimer's treatment.
Read more →About Grifols, S.A.
BIOPHARMAWATCH ELITE PLUS
Trade the next GRFS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime